Results 41 to 50 of about 35,799 (236)

Familial Micronodular Adrenocortical Disease, Cushing Syndrome, and Mutations of the Gene Encoding Phosphodiesterase 11A4 ( PDE11A) [PDF]

open access: yes, 2014
We present the pathologic findings in the adrenal glands of 4 patients, aged 10 to 38 years, with Cushing syndrome and germline inactivating mutations of the gene PDE11A4 that encodes phosphodiesterase11A4. The gene is expressed in the adrenal cortex and
Bertherat, J.   +3 more
core   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Cushing syndrome, metabolic syndrome and inflammation: a suggested way out [PDF]

open access: yes, 2013
Endogenous hypercortisolism is associated with an increased cardiovascular risk. Cushing Syndrome (CS) shares many clinical features with metabolic syndrome, including abdominal obesity, systemic arterial hypertension, insulin resistance, dyslipidemia ...
Bellastella, Giuseppe   +5 more
core   +1 more source

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

open access: yesAdvanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv   +10 more
wiley   +1 more source

Unilateral nodular adrenal hyperplasia: Case series

open access: yesAfrican Journal of Urology, 2016
Introduction: Nodular adrenal hyperplasia is one of rare causes of adrenocortical hyperplasia. The disease usually presents bilaterally. Few publications discussed the possibility of unilateral disease, in association with hyperaldosteronism or Cushing ...
A.F. Kotb, M.A. Atta
doaj   +1 more source

Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017 [PDF]

open access: yes, 2017
The most common endocrinopathy associated with McCune-Albright Syndrome (MAS) is peripheral precocious puberty (PP) which occurs far more often in girls than in boys.
Eugster, Erica A., Neyman, Anna
core   +1 more source

Hyperandrogenemia Induces Trophoblast Ferroptosis and Early Pregnancy Loss in Patients With PCOS via CMA‐Dependent FTH1 Degradation

open access: yesAdvanced Science, EarlyView.
In PCOS patients with hyperandrogenemia, decreased ferritin heavy chain 1 (FTH1) causes Fe2⁺ overload and ferroptosis in trophoblasts. Androgens induce FTH1 protein degradation via AR‐LAMP2A‐mediated chaperone‐mediated autophagy pathway, leading to placental development disruption and early pregnancy loss. Metformin mitigates androgen‐induced placental
Hanjing Zhou   +10 more
wiley   +1 more source

Cushing syndrome

open access: yesSri Lanka Journal of Diabetes Endocrinology and Metabolism, 2014
DOI: http://dx.doi.org/10.4038/sjdem.v4i1.7260 Sri Lanka Journal of Diabetes, Endocrinology and Metabolism 2014; 4: S1 ...
Noel Somasundaram   +18 more
doaj   +1 more source

Development of serum dexamethasone radioimmunoassay to corroborate Cushing's syndrome diagnosis [PDF]

open access: yes, 2011
INTRODUCTION: The 1 mg dexamethasone suppression test (DxST) is widely used to screen Cushing's syndrome (CS) due to its high diagnostic accuracy. CS is an endocrine-metabolic disorder caused by hypercorticism, which is characterized by the absence of ...
Hayashi, Lilian Fukusima   +4 more
core   +3 more sources

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy